Utah, USA-based privately-held biotech Halia Therapeutics has announced promising top-line data resulting in the advancement ...

Neuraxpharm Group, a privately-held specialty pharma focused on central nervous system (CNS) disorders, and Greek drugmaker ...

California-based Angitia Biopharmaceuticals, a biotech focused on the discovery and development of innovative therapeutics ...

US clinical-stage biotech Q32 Bio (Nasdaq: QTTB) saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed ...

Chinese biopharma Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

Accent Therapeutics appoints Serena Silver as chief scientific officer as it advances Phase I/II ATX-559 trials for advanced ...

Merck KGaA appoints Miguel Fernández Alcalde as president of its US biopharmaceutical division EMD Serono to strengthen the ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...

Minoryx Therapeutics plans to submit European approval for leriglitazone after Phase II NEXUS trial shows 35% disease arrest ...

Santhera Pharmaceuticals gains approval in China for Agamree, the first Duchenne muscular dystrophy therapy available for ...